Next Article in Journal
Astaxanthin Suppresses PM2.5-Induced Neuroinflammation by Regulating Akt Phosphorylation in BV-2 Microglial Cells
Next Article in Special Issue
Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer
Previous Article in Journal
Biomarkers Suggesting Favorable Prognostic Outcomes in Sudden Sensorineural Hearing Loss
Previous Article in Special Issue
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma
Open AccessReview

Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments

by 1,2,†, 3,†, 1,2,* and 1,4,*
1
School of Dentistry, China Medical University, Taichung 40402, Taiwan
2
Department of Dentistry, China Medical University Hospital, Taichung City 404332, Taiwan
3
Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan
4
Department of Dental Hygiene, China Medical University, Taichung 40402, Taiwan
*
Authors to whom correspondence should be addressed.
These authors equally contributed to this work.
Int. J. Mol. Sci. 2020, 21(19), 7231; https://doi.org/10.3390/ijms21197231
Received: 31 August 2020 / Revised: 24 September 2020 / Accepted: 26 September 2020 / Published: 30 September 2020
Oral submucous fibrosis (OSF) is a collagen deposition disorder that affects a patient’s oral function and quality of life. It may also potentially transform into malignancy. This review summarizes the risk factors, pathogenic mechanisms, and treatments of OSF based on clinical and bio-molecular evidence. Betel nut chewing is a major risk factor that causes OSF in Asia. However, no direct evidence of arecoline-induced carcinogenesis has been found in animal models. Despite identification of numerous biomarkers of OSF lesions and conducting trials with different drug combinations, clinicians still adopt conservative treatments that primarily focus on relieving the symptoms of OSF. Treatments focus on reducing inflammation and improving mouth opening to improve a patient’s quality of life. In conclusion, high-quality clinical studies are needed to aid clinicians in developing and applying molecular biomarkers as well as standard treatment guidelines. View Full-Text
Keywords: biomarkers; epidemiology; oral submucous fibrosis (OSF); pre-malignant disorders; therapeutic interventions biomarkers; epidemiology; oral submucous fibrosis (OSF); pre-malignant disorders; therapeutic interventions
MDPI and ACS Style

Shen, Y.-W.; Shih, Y.-H.; Fuh, L.-J.; Shieh, T.-M. Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments. Int. J. Mol. Sci. 2020, 21, 7231. https://doi.org/10.3390/ijms21197231

AMA Style

Shen Y-W, Shih Y-H, Fuh L-J, Shieh T-M. Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments. International Journal of Molecular Sciences. 2020; 21(19):7231. https://doi.org/10.3390/ijms21197231

Chicago/Turabian Style

Shen, Yen-Wen; Shih, Yin-Hwa; Fuh, Lih-Jyh; Shieh, Tzong-Ming. 2020. "Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments" Int. J. Mol. Sci. 21, no. 19: 7231. https://doi.org/10.3390/ijms21197231

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop